Drug Database
AT

atenolol (Anselol / atenolol, Douglas)

✓ Approved

Douglas Pharmaceuticals Limited · ADRB1 · 小分子

什么是 atenolol?

atenolol 是一种小分子,由Douglas Pharmaceuticals Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Anselol, atenolol, Douglas
公司Douglas Pharmaceuticals Limited
药物类别小分子
分子靶点ADRB1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

atenolol 作用于 1 个分子靶点:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

atenolol 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedRespiratory medicine case reports2026-11-13

Reproducible vasovagal syncope triggered by indwelling pleural catheter drainage: A case of vagal hypersensitivity.

Shah Parita P, Colin Lennon L, Lien Irvin I, Jani Pushan P

Indwelling pleural catheters (IPCs) are generally safe and effective for symptomatic relief and drainage of malignant pleural effusions. Common complications include infection and blockage; however, repeated vasovagal syncopal symptoms during drainage are rare. We report the case of a 62-year-old male with metastatic lung adenocarcinoma complicated by recurrent malignant pleural effusions, who experienced repeated near-syncopal episodes with profound bradycardia (HR < 30 bpm) during the first thoracentesis, during IPC placement and recurrent vasovagal symptoms during subsequent drainage episodes of the catheter at home for two more times. Symptoms were reproducible, occurring even with small-volume removals (<300mL). These episodes were theorized to be due to direct and indirect stimulation of the vagal nerve. The patient was also on atenolol (a betablocker), meaning that his compensatory sympathetic response may have been blunted. Management focused on discontinuation of atenolol and modification of IPC drainage technique (supine positioning and slower flow), which mitigated the episodes. Clinicians must recognize that vagal hypersensitivity, near syncope, and hemodynamic instability are possible complications of IPC drainage.

PMID 43022726
阅读全文 →
PubMedNew biotechnology2026-11-12

Application of bivalve shells for the removal of trace levels of micropollutants from wastewater under continuous flow conditions.

Jesus Fátima F, Sousa Érika M L ÉML, Pascoal Érica É, Calisto Vânia V et al.

Advanced nature-based systems such as METland® efficiently remove contaminants of emerging concern from municipal wastewater, yet a residual mixture of compounds often persists. This study evaluated bivalve shells as a low-cost polishing step for METland® effluent in two steps: preliminary fixed-bed adsorption experiment comparing the performance of whole clam shells, pyrolyzed clam shells and pyrolyzed oyster shells; a large-scale fixed-bed removal experiment using raw clam shells, calcined clam shells and a shell mixture, integrating LC-MS/MS multiresidue analysis and ecotoxicological assays. Overall, METland® reduced the contaminant load by more than 90%, but the effluent was dominated by persistent compounds and TPs, notably antipyrine derivatives and atenolol acid. In the preliminary experiment, shell-based polishing achieved additional removal (~20-90%) with consistently high reductions for valsartan, paraxanthine, and atenolol acid. In the large-scale experiment, caffeine and paraxanthine showed > 85% removal after 7 days, whereas the atenolol/atenolol acid system showed evidence of pH-induced transformation within the columns, affecting the results. After column treatment, pH increased from approximately 6-7 in the METland® effluent to near-neutral or mildly alkaline values (~7-8), accompanied by an increase in inorganic carbon. Ecotoxicity was largely mitigated by METland®, and shell polishing provided minor additional improvements. This study demonstrates the potential of waste-derived bivalve shells as a sustainable polishing step for METland® effluents under continuous-flow conditions, providing one of the few evaluations of shell-based materials using real wastewater matrices, operational conditions and environmentally relevant contaminant concentrations.

PMID 43020267
阅读全文 →
PubMedInternational journal of pediatric otorhinolaryngology2026-11-11

Management of complex head and neck infantile hemangioma with atenolol - A single-institution 5-year case series.

Jeoung Sarah S, Pauley Jordan J, Klatte Hannah H, El-Feghaly Jinia J et al.

Infantile hemangioma (IH) occurs frequently in the head and neck region. When the IH has no cutaneous involvement or in an area difficult to examine, the pediatric otolaryngologist may be expected to manage. While propranolol is the standard treatment, atenolol is a promising alternative. Some pediatric otolaryngologists are hesitant to prescribe a hemodynamically active medication for an infant. This study describes the experience with atenolol in managing complicated head and neck IHs and hemodynamic changes occurring during medication initiation. This is a case-series of all patients treated with atenolol for IH from 2019 to 2024 at a single tertiary care pediatric otolaryngology practice. Twenty-four patients with head and neck IH were included. 67% were female (n = 16). The most common locations were the nose/nasal cavity (n = 7), cheeks/parotid (n = 6), lip (n = 6), and ear (n = 2). The majority were deep IH (n = 15). Most patients were started on atenolol in the outpatient setting (n = 18) at the mean age of 4.75 months. The average treatment duration was 7.8 months and 75% showed no evidence of rebound growth (n = 19) after medication discontinuation. All cases showed either a partial or complete response to treatment. Though there were statistically significant drops in certain vital signs, no patient required any intervention during medication initiation. Atenolol is well-tolerated and effective for complicated head and neck IHs. It can be safely initiated by the pediatric otolaryngologist in the outpatient clinic.

PMID 43014076
阅读全文 →
PubMedArchives of toxicology2026-11-09

CYP450 quantification and metabolic activation capacity of rat and hamster liver S9 fractions: implications for nitrosamine mutagenicity testing.

Dieckhoff Jessica J, Bringezu Frank F, Singh Jasjot J, Moniot Sébastien S et al.

N-nitrosamine impurities are a major concern in the pharmaceutical industry and public safety. The assessment of this chemically diverse group using conventional regulatory test batteries, including the Ames test (OECD TG 471), remains challenging. Consequently, refined strategies such as the Enhanced Ames Test (EAT) have been developed and recommended by regulatory authorities, requiring 30% induced rat and hamster S9. Recently, we showed that hamster S9 metabolizes short-chain N-nitrosamines more efficiently than rat S9, likely due to differences in the induction pattern of metabolizing enzymes. Metabolic activation by cytochrome P450 isoenzymes (CYP) is a critical step in the bioactivation of N-nitrosamines. Building on our previous publication, the present work focusses on key CYPs and sets the proteome data into perspective with in vitro mutagenicity data for selected N-nitrosamines. Targeted proteomics quantified CYP1A2, 2A6, 2C8/9/19, 2D6, 2E1, and 3A4 of rat and hamster orthologs in uninduced, Aroclor 1254-, and PB/NF-induced rat and hamster liver S9. In rat S9, induction markedly increased CYP1A2 and CYP3A1 (> 40-fold). For the selected set of CYPs, most protein levels in hamster S9 decreased or increased only slightly (< 6-fold) following induction, although baseline levels were higher than those in uninduced rat S9. Nevertheless, induced hamster S9 generated the strongest Ames responses for NDBA and 1-CPNP, indicating that induction enhances CYP activity beyond protein quantity alone. N-nitroso-atenolol was negative under all rat S9 conditions but positive in TA1535 only with induced hamster S9, indicating that larger NDSRIs require elevated metabolic activity for detection. These findings provide a mechanistic basis for species- and induction-specific differences in mutagenicity detection and contribute to a better understanding of the metabolic activation capacity of S9.

PMID 43002211
阅读全文 →
PubMedCureus2026-10-23

Newly Diagnosed Graves' Disease Followed by the Discovery of a Cavernous Internal Carotid Artery Aneurysm Causing Panhypopituitarism: A Case Report.

Touffaha Ibrahim M IM, Elhomsy Georges G

Sellar and parasellar vascular lesions are rare causes of pituitary dysfunction and may mimic pituitary adenomas or other sellar masses. Cavernous internal carotid artery (ICA) aneurysms can cause hypopituitarism through compression of the pituitary gland or stalk, but diagnosis may be delayed when symptoms are initially attributed to a more common endocrine disorder. We report a 37-year-old man who presented with six weeks of unintentional weight loss, fatigue, heat intolerance, excessive sweating, anxiety, tremor, and tachycardia. Initial evaluation showed suppressed thyroid-stimulating hormone (TSH), elevated total triiodothyronine (T3), positive thyrotropin receptor antibody, positive thyroid-stimulating immunoglobulin, and a hypervascular thyroid gland on ultrasound, consistent with Graves' disease. He was started on methimazole and atenolol. Although thyroid function tests improved, he developed persistent neck discomfort, prompting contrast-enhanced computed tomography (CT), which revealed an enhancing sellar mass. Magnetic resonance imaging (MRI) showed a T2-hypointense sellar lesion with internal flow artifact, and CT angiography confirmed a saccular aneurysm of the cavernous segment of the right ICA. Pituitary hormone evaluation demonstrated secondary adrenal insufficiency, central hypothyroidism, hypogonadotropic hypogonadism, growth hormone (GH) deficiency, and mild hyperprolactinemia, consistent with panhypopituitarism from pituitary compression. The patient was started on prednisone and levothyroxine, and atenolol and prednisone were subsequently discontinued before endovascular embolization was performed. At follow-up, symptoms improved, but panhypopituitarism persisted. This case highlights the importance of reassessing patients when endocrine symptoms evolve despite an initially appropriate diagnosis.

PMID 42910339
阅读全文 →
PubMedBriefings in bioinformatics2026-10-19

Metabolomics workbench: data-driven classification and correlation analysis between metabolite classes, biomarkers, and drugs.

Khandokhin Mikhail M MM, Sokolov Aleksandr A, Oskolkov Nikolay N, Fredriksson Robert R et al.

Public repositories now accumulate an unprecedented amount of metabolomics data. Despite the opportunities for large-scale meta-analyses opened by these repositories, the deposited data rarely becomes systematically re-analyzed. We conducted a systematic metadata-based re-analysis of all human blood metabolomics studies in the Metabolomics Workbench performed using Orbitrap or QTOF mass spectrometry, encompassing 44 165 samples. After harmonizing metabolites with PubChem identifiers and embedding them using SMILES representations, we generated a map of 6752 blood metabolites forming 25 structural clusters, and subsequently performed correlation analysis between these clusters, biomarkers, and drugs. Analysis of 337 120 metabolite pairs detected in at least 10 studies showed that structurally related clusters display correlated abundances (ρ up to 0.6). Correlation patterns among established clinical biomarkers revealed candidate metabolic correlates, several with ρ > 0.7. We also developed open-source software enabling similar analyses for any metabolite across the Workbench data explored. Additionally, curating drug-containing datasets enabled meta-analyses for compounds such as acetaminophen, metoprolol, and atenolol, identifying both known and novel metabolic signatures. Besides the biological insights, we have found that Orbitrap and QTOF tend to detect different metabolites, but they give quantitatively coherent results on overlapping compounds. Overall, the present study provides the methodology and software to perform large-scale mining of public metabolomics data enabling its re-analysis to obtain novel biomedical insights.

PMID 42894388
阅读全文 →

注册免费账户还可查看另外 7893 篇文献

免费注册查看全部文献 →

了解更多atenolol